Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -40.75% is 74% above its 5-year average of -156.11%, near the high end of its 5-year range (-486.07%–0.83%).
As of the fiscal period ended Tuesday, March 31, 2026. 13.54% below its 12-month average of -35.89%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2026-03-31.
RETURN ON EQUITY (ROE)
-40.75%
RETURN ON EQUITY (ROE) AVG TTM
-35.89%
RETURN ON EQUITY (ROE) AVG 3Y
-218.64%
RETURN ON EQUITY (ROE) AVG 5Y
-156.11%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.54%
CURRENT VS 3Y AVG
+81.36%
CURRENT VS 5Y AVG
+73.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
+3.00%
vs the sector median at left
Paranovus Entertainment Technology Ltd.
Market Cap
$3.28M
Return on Equity (ROE)
-40.75%
TTM Avg
-35.89%
3Y Avg
-218.64%
5Y Avg
-156.11%
Market Cap
$3.30M
Return on Equity (ROE)
-591.60%
TTM Avg
-213.16%
3Y Avg
-150.57%
5Y Avg
-4.48%
Market Cap
$3.25M
Return on Equity (ROE)
120.45%
TTM Avg
927.43%
3Y Avg
433.61%
5Y Avg
340.10%
Market Cap
$3.21M
Return on Equity (ROE)
-133.43%
TTM Avg
-203.84%
3Y Avg
-174.81%
5Y Avg
-140.61%
Market Cap
$3.14M
Return on Equity (ROE)
-365.43%
TTM Avg
-2048.73%
3Y Avg
-1082.52%
5Y Avg
-614.77%
Market Cap
$3.49M
Return on Equity (ROE)
-40.20%
TTM Avg
193.27%
3Y Avg
-10433.46%
5Y Avg
-6975.64%
Market Cap
$3.07M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
Market Cap
$3.50M
Return on Equity (ROE)
-89.85%
TTM Avg
30.83%
3Y Avg
-183.24%
5Y Avg
-146.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Paranovus Entertainment Technology Ltd. (PAVS) | $3.28M | -40.75% | -35.89% | -218.64% | -156.11% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -591.60% | -213.16% | -150.57% | -4.48% |
| MBody AI Ltd. (MBAI)vs › | $3.25M | 120.45% | 927.43% | 433.61% | 340.10% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.21M | -133.43% | -203.84% | -174.81% | -140.61% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.14M | -365.43% | -2048.73% | -1082.52% | -614.77% |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -40.20% | 193.27% | -10433.46% | -6975.64% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.07M | N/A | -236.13% | -104.67% | -48.54% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.50M | -89.85% | 30.83% | -183.24% | -146.59% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -282.13% | -313.25% | -153.55% | -153.55% |
ROE
-40.8%
ROA
-34.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-03-31 | -40.75% |
| 2025-03-31 | -31.03% |
| 2024-03-31 | -316.70% |
| 2023-03-31 | -486.07% |
| 2022-03-31 | -62.96% |
| 2021-03-31 | 0.83% |
| 2020-03-31 | 15.94% |
| 2019-03-31 | 30.73% |
| 2018-03-31 | 39.26% |
| 2017-03-31 | 62.27% |
